Hengrui Pharmaceuticals R&D strength (tech talent demand and pay)

What is the demand for tech talent at Hengrui Pharmaceuticals? Based on job postings in the past year, “医疗卫生/美容保健类”占40.2%,“生物/制药/化工/环保类”占21.5%,“其他(研发和技术类)”占11.8%,“科研类”占10.1%,“计算机/网络/技术类”占8.2%,“机械/仪器仪表类”占1.5%,“电气/能源/动力类”占0.9%,“电子/电器/通信技术类”占0.6%,“农林渔类”占0.4%,“美术/设计/创意类”占0.2%. For reference only.

Master's degree job demand analysis at Hengrui Pharmaceuticals (More)

?
Growth rate
2026 vs 2025
  • 2025: Up 65%
  • 2024: Up 218%
  • 2023: Up 23%
  • 2022: Down 57%
Hengrui Pharmaceuticals master's hiring over the years:
* Hiring volume was generally low in 2020-2022 due to the pandemic

PhD job demand analysis at Hengrui Pharmaceuticals (More)

?
Growth rate
2026 vs 2025
  • 2025: Up 140%
  • 2024: Up 216%
  • 2023: Down 60%
  • 2022: Down 47%
Hengrui Pharmaceuticals PhD hiring over the years: 2026: 485 more positions than 2025
* Hiring volume was generally low in 2020-2022 due to the pandemic

Hengrui Pharmaceuticals honors, qualifications & industry associations

People who follow Hengrui Pharmaceuticals also follow

Hengrui Pharmaceuticals Competitors (Similar Companies)

“To develop high-quality biologics that are accessible and affordable f”
“A renowned enterprise in China's liver disease and anti-tumor fields”
“Continuously innovating to bring patients medicines that significantly”
“Seek and strive, protect and heal all beings”
“Accelerating global biologic drug R&D processes, reducing R&D costs, a”
“Caring for life, safeguarding health”
“Dedicated to the research and development of molecularly targeted drug”
“Professional services for the entire clinical trial process of drug pr”
“Developing innovative drugs to improve human health”
“Technological innovation and commercial application of pharmaceutical ”
“One of the leading enterprises in the pharmaceutical industry”
“Helping partners successfully develop new drugs, reducing R&D costs an”
“A large traditional Chinese medicine enterprise integrating R&D, produ”
“Helping patients access more effective medicines sooner”
“A leading open-access capability and technology platform company for p”